Sponsor: MUSC
Sponsor Study ID: 102727
Study Title: Pembrolizumab In Combination With Anti platelet Therapy For Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck
CTO #: 102727
NCT Number: NCT03245489
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lip, Oral Cavity and Pharynx
Study Objectives: To determine if anti-platelet therapy (acetylsalicylic acid, clopidogrel) combined with anti-PD-1 immunotherapy (pembrolizumab) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) is able to induce a more favorable immunologic response profile than immunotherapy alone.